Evidence map›Paper›PMID 38434149›Full record

ArticleMedical devices (Auckland, N.Z.)2024

Testing a Cloud-Based Model for Active Surveillance of Medical Devices with Analyses of Coronary Stent Safety Using the Data Extraction and Longitudinal Trend Analysis (DELTA) System.

Joseph P Drozda, Henry Ssemaganda, Edward A Frankenberger, Eric Brandt, Susan Robbins, Neha Khairnar, Alexandra Cha, Frederic S Resnic

Open access · goldAbstract read
In one paragraph

Article in Medical devices (Auckland, N.Z.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Joseph P Drozda *Retiree, Mercy, Chesterfield, MO, USA.ORCID 0000-0001-9181-8534
Henry Ssemaganda *Comparative Effectiveness Research Institute, Lahey Hospital and Medical Center, Burlington, MA, USA.
Edward A Frankenberger *Freenome, South San Francisco, CA, USA.ORCID 0000-0003-4951-4312
Eric Brandt *Research, Mercy, Chesterfield, MO, USA.
Susan Robbins *Comparative Effectiveness Research Institute, Lahey Hospital and Medical Center, Burlington, MA, USA.
Neha Khairnar *Comparative Effectiveness Research Institute, Lahey Hospital and Medical Center, Burlington, MA, USA.
Alexandra Cha *Booz Allen Hamilton, Bethesda, MD, USA.
Frederic S Resnic *Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, MA, USA.
Lahey Medical Center · USBooz Allen Hamilton (United States) · USFreenome (United States) · USLahey Hospital and Medical Center · USMercy Research · USSisters of Mercy Health System · US

Funding

NESTcc Renewal -Continuation of the National Evaluation System for Health Technology (NEST) Coordinating Center (CC)U01FD006292 · FDA · MEDICAL DEVICE INNOVATION CONSORTIUM · PI SMITH, RICHARD · 2018 to 2025
$76.1M
FDA HHS U01 FD006292
6 · The paper itself

Abstract

Objective: To demonstrate the use of the Data Extraction and Longitudinal Trend Analysis (DELTA) system in the National Evaluation System for health Technology's (NEST) medical device surveillance cloud environment by analyzing coronary stent safety using real world clinical data and comparing results to clinical trial findings. Design and Setting: Electronic health record (EHR) data from two health systems, the Social Security Death Master File, and device databases were ingested into the NEST cloud, and safety analyses of two stents were performed using DELTA. Participants and Interventions: This is an observational study of patients receiving zotarolimus drug-eluting coronary stents (ZES) or everolimus eluting coronary stents (EES) between July 1, 2015 and December 31, 2017. Results: After exclusions, 3334 patients receiving EES and 1002 receiving ZES were available for study. Analysis using inverse probability weighting showed no significant difference in one-year mortality or major adverse cardiac events (MACE) for EES compared to ZES [Mortality Odds Ratio 0.94 (95% CI 0.81-1.175); p = 0.780] [MACE Odds Ratio 1.04 (95% CI 0.92-1.16; p = 0.551]). Analysis using propensity matching showed no significant difference in EES one-year mortality (547 of 992 alive and available after censoring) compared to ZES (546 of 992) [Log-Rank statistic 0.3348 (p = 0.563)]. Conclusion: Automated cloud-based medical device safety surveillance using EHR data is feasible and was efficiently performed using DELTA. No statistically significant differences in 1-year safety outcomes between ZES and EES were identified using two statistical approaches, consistent with randomized trial findings.

Indexed as

active surveillancecardiac devicesoutcomes assessment (health care)real-world evidencesafety-based medical device withdrawals

Identifiers

PMID38434149
PMCPMC10908332
OpenAlexW4392202556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.